Core Insights - The article emphasizes the transition of robotics from prototype to revenue deployment, highlighting the importance of commercial readiness in the AI service robotics market [1][2] Group 1: Industry Trends - The shift towards commercialization readiness in robotics is characterized by clear ownership of intellectual property, engineering leadership tied to revenue performance, and validation through major technology showcases [1] - Companies that can transition from prototype demonstration to scalable deployment are positioned to define early Robotics-as-a-Service (RaaS) infrastructure, allowing businesses to adopt automation without significant upfront investments [1] Group 2: Company Focus - Nightfood Holdings Inc. and its subsidiary TechForce Robotics are navigating the transition by deploying AI-driven automation tailored to hospitality workflows, focusing on real-world deployment rather than remaining in pilot phases [2] - Nightfood Holdings is revolutionizing the hospitality industry by combining AI-powered robotics with strategic hotel acquisitions, aiming to improve hotel efficiency and reduce operating costs [3] Group 3: Market Position - Nightfood Holdings is strategically positioned to capitalize on the global service robotics market, which is expected to exceed $170 billion by 2030, through its dual focus on owning hotel properties and offering RaaS [4]

Core Insights - Polaryx Therapeutics is committed to developing disease-modifying therapies for rare pediatric lysosomal storage disorders (LSDs) and raising awareness within the rare disease community [2][4] Company Overview - Polaryx Therapeutics, founded in 2014, focuses on small molecule and gene therapy treatments for rare orphan LSDs, aiming to address significant unmet medical needs [8] - The company's lead candidate, PLX-200, is designed to target multiple LSDs and is currently advancing through clinical trials [8] Clinical Trials - The SOTERIA trial is a Phase 2, open-label, single-arm study aimed at evaluating the safety, tolerability, and clinical activity of PLX-200 across four rare LSDs: CLN2, CLN3, Krabbe disease, and Sandhoff disease [7] - The trial is expected to begin in the first half of 2026, with sites in the United States, Europe, and Asia [7] - SOTERIA is designed to be flexible and resource-efficient, potentially validating PLX-200's preclinical science while gathering important data for future clinical development [7] Rare Disease Context - LSDs are a group of over 50 inherited metabolic diseases caused by genetic mutations, affecting approximately 1 in 5,000 births [3][4] - The National Organization for Rare Diseases (NORD) defines a rare disease as one affecting fewer than 1 in 2,000 people globally, with about 70% starting in childhood [4] - More than 300 million people worldwide are affected by rare diseases, highlighting the urgent need for new treatments [4]

Core Viewpoint - A class action lawsuit has been filed against Snowflake Inc. for allegedly misleading investors about its business prospects during a specified period, leading to significant stock price declines following the disclosure of negative financial forecasts [1][2][3]. Group 1: Allegations and Misleading Statements - The lawsuit claims that Snowflake made repeated positive statements about its business state, including customer usage and product developments, while failing to disclose material negative impacts from product efficiency gains and tiered storage pricing [2]. - It is alleged that these positive statements lacked a reasonable basis due to undisclosed factors that were expected to negatively affect consumption and revenues [2]. Group 2: Financial Disclosure and Stock Impact - On February 28, 2024, Snowflake disclosed its financial results for the quarter ended January 31, 2024, which included forecasts of increased revenue headwinds due to product efficiency gains and tiered storage pricing [3]. - Following this announcement, Snowflake's Class A common stock price fell by $41.72, or 18.14%, from $230.00 to $188.28 per share [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Snowflake and can contact Robbins LLP if they wish to serve as lead plaintiffs [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 4: Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

SARASOTA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Trump Media & Technology Group Corp. (Nasdaq, NYSE Texas: DJT) (“TMTG”), TAE Technologies, Inc. (“TAE”), and Texas Ventures Acquisition III Corp. (Nasdaq: TVA) (“Texas Ventures III”) today announced that they are engaged in ongoing discussions regarding a potential spin-off by TMTG of businesses including Truth Social into a new publicly-traded company (“SpinCo”) following the closing of the previously announced pending merger transaction between TMTG and TA ...

During one of my trips to India, I wanted to buy a pair of sandals suited for the monsoon weather conditions. It needs to be waterproof and comfortable for everyday use in humid conditions, so I stopped at aRida Morwa is a former investment and commercial Banker, with over 35 years of experience. He has been advising individual and institutional clients on high-yield investment strategies since 1991. Rida Morwa leads the Investing Group High Dividend Opportunities where he teams up with some of Seeking Alph ...

WEST SENECA, NY / ACCESS Newswire / February 27, 2026 / Projections often capture attention. Measurable progress builds confidence. ...

Core Viewpoint - CLPS Incorporation will announce its financial results for the first half of fiscal 2026 on March 6, 2026, before market opening [1] Company Overview - CLPS Incorporation, established in 2005 and headquartered in Hong Kong, focuses on digital transformation and operational efficiency through innovations in artificial intelligence, cloud computing, and big data [1] - The company operates across 10 countries with strategic hubs in Shanghai, Singapore, and California, supported by subsidiaries in Japan and the UAE [1] - CLPS's business lines include fintech, payment and credit services, e-commerce, education, and global tourism integrated with transportation services [1] Financial Announcement - The financial results will cover the six months ended December 31, 2025, marking the first half of the Company's fiscal year 2026 [1]

Powered by XTEND’s proprietary XOS platform, the Seek & Strike demonstration validates scalable, human-guided autonomous fleets for complex defense missions Previously Announced: XTEND and JFB Construction to Combine in All-Stock Transaction, Backed by Strategic Investors; Expected to Close in the first half of 2026 and List on a U.S. national exchange as “XTND” TAMPA BAY, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTEND, a leader in software systems and artificial intelligence-powered robotics, deployed in hi ...

Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences comp ...

NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- AMC Robotics Corporation (Nasdaq: AMCI) (“AMC Robotics” or the “Company”), an AI-driven robotics solutions provider, today announced a strategic collaboration with Sunward Logistics USA LLC (“Sunward”) in connection with the deployment and field validation of its next-generation warehouse sorting robot, NovaArm™. Under the collaboration, Sunward will serve as AMC Robotics’ first commercial deployment customer and its first strategic customer for NovaArm™. The syst ...